Red Light Holland (TRIP) reported quarterly financial results including $622K in revenue (up 28% over the previous quarter), a gross profit of $232 (up 48%) and $27.3M in cash.
Toronto, Ontario–(Newsfile Corp. – February 28, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation is pleased to announce its wholly owned subsidiary SR Wholesale in the Netherlands (“SR Wholesale“), has signed an exclusive distribution deal with Conor McGregor’s innovative sports recovery line, TIDL Sport.
Figure 1: SR Wholesale signs exclusive distribution deal with TIDL Sport – Conor McGregor’s innovative Sports Recovery line.
TIDL Sport products combine plant based therapy with exercise science and cryotherapy to assist active lifestyle enthusiasts. True sports recovery goes beyond temporary pain relief, and TIDL Sport products are scientifically curated with ingredients that target inflammation, the foundation of post exercise pain and soreness. The products have been clinically proven to reduce pain and aim to help consumers return to the activities that they love sooner, and pain free.
“I’ve been putting extra focus on my overall health for years now, which is why I’m so pleased that TIDL Sport is partnering with Red Light Holland. Our combined efforts to distribute products with the goal of education around sports recovery – both mentally and physically are where Red Light Holland and TIDL Sport are progressive and aligned.” said Conor McGregor.
TIDL Sport products are designed for the active lifestyle, no matter what the sport. Consumers range from weekend warriors to professional athletes, all whom recognize the importance of recovery and self care. The products focus on different segments of recovery, including relief with the current products and a pipeline that focuses on body recharge and nutrient replenishment.
“We are delighted to be partnering with Conor McGregor and The Anthos Group as Red Light Holland’s wholly-owned subsidiary SR Wholesale plans to be a big part of the distribution for Conor’s next generation sports recovery line – TIDL Sport,” said Todd Shapiro, CEO and Director of Red Light Holland. “The foundation of TIDL Sport and Conor McGregor are completely aligned with Red Light Holland. Together we believe in naturally occurring therapies, healthy and active lifestyles and living in the moment with the goal of long-term recovery while focusing on the betterment of physical and mental health. We see a large opportunity to educate around recovery and wellness and look forward to working closely with Conor and Badal Shah, Chief Executive Officer at The Anthos Group now and into the future.”
“One of Red Light Holland’s focus for 2022 is Mind to Toe wellness. Everyone at SR Wholesale is very excited to now have the access to distribute TIDL Sport, especially in the Netherlands and potentially across Europe – where Conor McGregor is beloved!” said Hans Derix, President of Red Light Holland.
Under the terms of the deal, Red Light Holland’s wholly-owned subsidiary SR Wholesale’s territory to distribute TIDL Sport, shall mean the country of The Netherlands and on a case by case basis, where no there is no conflict with an existing TIDL Sport Distributor, into all regions of Europe.
The brand’s flagship product, the TIDL Sport Plant-Powered Cryotherapy Topical Spray, delivers powerful relief through cryotherapy and novel plant science, delivering immediate pain relief and leaving athletes feeling refreshed as a part of the active lifestyle. The revolutionary topical spray has 360° spray technology for easy, full body self-application and promotes long term healing by addressing pain and inflammation directly at the source. The plant based ingredients in TIDL Sport range from plant derived extracts to well known anti-inflammatory agents that are all organic in nature. The enhanced touch-free formula sprays on clean with an immediate cooling relief, which increases blood flow to the site of application and enables the plant based ingredients to self absorb and go to work.
In addition, the Company’s board of directors approved the grant of 6,600,000 options and awarded 850,000 restricted stock units to certain directors, officers, and consultants of the Company. Each option will entitle the holder thereof to acquire one common share in the capital of Company for a period of three years from the date of issuance, which is expected to on or before March 7, 2022, at an exercise price equal to the greater of (i) $0.12, and (ii) the Company’s closing price on the Canadian Securities Exchange on the day prior to issuance, and subject to the terms and conditions of the Company’s stock option plan. The options will vest quarterly at the end of each fiscal quarter of the Company’s 2023 fiscal year. The options granted to directors of the Company are compensation for their services over the fiscal year ending March 31, 2023. All options and restricted stock units awards will be subject to a hold period of four months plus one day from the date of issuance.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: Todd@RedLight.co
Website: www.RedLight.co
About TIDL Sport
TIDL Sport infuses plant powered therapy with fitness and nutrition science to meet the needs of athletes to perform at the highest level. The flagship product is a plant-powered cryotherapy topical spray that has 360° spray technology for easy, full body self-application. TIDL Sport products are available in select national retailers in the U.S., globally in over 25 countries, and on the company website: www.tidlsport.com
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to: statements with respect to the Company’s plans for its wholly-owned subsidiary SR Wholesale to be a big part of the distribution for Conor’s next generation sports recovery line – TIDL Sport, the Company’s plans to work with Conor and Badal Shah in the future, and statements with respect to the Company’s business focus in 2022.
Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the COVID-19 pandemic impact on the Canadian economy and Red Light Holland’s business, the Company’s ability to carry out its plans with respect to SR Wholesale distributing Conor’s products, the willingness and ability of Conor and Badal Shah to continue working with SR Wholesale and the Company, no change to laws or regulations that negatively affect Red Light Holland’s business; there will be a demand for Red Light Holland’s products in the future; no unanticipated expenses or costs arise. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to continue as a going concern; the inability of the Company to obtain all necessary governmental and/or other regulatory approvals, licenses, and permits necessary to operate and expand the Company’s facilities; the effect of regulatory and/or political change and its effect on the legislation and regulations surrounding the psychedelics industry; negative perception of the medical-use and adult-use psilocybin industry; the potential unviability of psilocybin for medical and/or scientific purposes; the inability of the Company to continue its growth; the Company’s limited operating history; reliance on management; the Company’s requirements for additional financing; and competition for mental health and wellness investments.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Who else is counting down the days til the Daily Mushroom + Entheon Biomedical Mental Health Town Hall?? If you haven’t registered yet, you can do so here. What are you waiting for? It’s totally free and virtual so anyone can attend.
Here’s what’s in store for you in today’s issue:
🍄 The psychedelic that’s already in our brains
🍄 MAPS receives Innovation Passport for MDMA therapy 🎉
🍄 First commercial study of LSD in 40 years
🍄 Will Oregon legalize microdosing?
🍄 And more.
In this episode of The Daily Mushroom Podcast, we have Cory Firth, Executive Director of The Canadian Psychedelic Association and founder of DoseDay! Cory opens about his battle with mental health and shares his experience with psychedelics in his quest to find meaning in his life. He also talks about how he got himself into a 7 ayahuasca retreat and what that journey gave him.
MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.
The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation.
Shares of MNMD spiked 30% following the announcement 💰
A recent study found pure MDMA administered in a clinic does not have the “come down” effect that recreational users often report the day after dosing.
Participants maintained a positive mood during the week following the dose. Plus, no participant had used or desired to use illegal MDMA at the 3 month and 6 month follow ups.
The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.
Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.
Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.
Maybe that’s why Mario can jump so high without destroying his joints 😉
The Innovation Passport will make MDMA therapy for PTSD widely available in the UK, as rapidly as possible!
The Multidisciplinary Association for Psychedelic Studies (MAPS) found that 88% of patients had a reduction in PTSD symptoms after three MDMA sessions in conjunction with trauma-focused therapy.
The organization was granted an Innovation Passport for the treatment – a UK designation that speeds up the timeline for approval of innovative medicines for life-threatening conditions (similar to Breakthrough Therapy Designations in the US, which the treatment received in 2017).
Did you know that one of the most promising addiction treatments is a psychedelic compound that’s found throughout nature and is present within the human body?
It’s called DMT (N,N-Dimethyltryptamine) and is thought to be produced in the brain’s pineal gland. DMT is released in large amounts when we dream and when we die.
Learn what leading DMT experts have discovered at the Daily Mushroom + Entheon Biomedical Mental Health Town Hall on Thursday, Feb. 3rd. Register now for free to get the inside scoop 👇
CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).
The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP.
The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.
Beckley Psytech began training psychotherapists for a phase II study on 5-MeO-DMT for treatment-resistant depression through Fluence’s interactive training program. Within the next year, Beckley aims to train 80 psychotherapists on how to administer psychedelic therapy.
Mydecine (MYCO) is partnering with a UK-based charity called Combat Stress and the King’s College London to study psilocybin therapy as a treatment for veterans with severe, treatment-resistant PTSD.
Psygen Labs entered into an agreement to supply Universal Ibogaine (IBO) with ibogaine for an upcoming clinical trial on opioid addiction.
atai Life Sciences (ATAI) launched a wholly owned platform company called Invyxis, which will focus on developing novel compounds that target serotonin 5-HT2A receptors.
Akome Biotech, a subsidiary of Core One Labs’ (COOL), signed a consulting agreement with the University of Barcelona to develop psychedelic treatments for depression, stroke, Parkinson’s, and Alzheimer’s.
Ketamine One (MEDI) changed its name to Wellbeing Digital Sciences and partnered with Nova Mentis (NM) to study psilocybin microdosing for fragile x syndrome.
But one question remains unanswered: will the new program include microdosing?
For the past year, the Oregon Health Authority has been planning the regulatory framework to implement Measure 109, which legalized psilocybin sessions under the care of licensed facilitators. The program is on schedule to roll out at the beginning of 2023.
At the latest public Zoom meeting, a push to include microdosing in the program received backlash from some advisory board members, but others thought it was worth considering. Members have until the end of June to reach a consensus.
The first bill would promote research focused on treating depression and anxiety in veterans. The second would promote research into 10 different conditions and reduce the penalty for psilocybin possession to a fine.
CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).
The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP.
The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.
Thank you to everyone who registered for our Mental Health Town Hall. We can’t wait to connect with you! If you haven’t signed up yet, don’t worry, it’s not too late. Keep reading for details.
Here’s what’s in store for you in today’s issue:
🍄 How psychedelics helped an ancient empire maintain power
🍄 Add some ecstasy to your sex life
🍄 Microdosing DMT
🍄 Australian gov’t funds 2 psychedelic studies
🍄 And more.
In this episode of the Daily Mushroom Podcast, we have Juan Pablo Cappello, co-founder and CEO of Nue Life Health. Nue Life’s at-home ketamine wellness program is proving to be highly beneficial for patients with treatment-resistant depression. The key is in the company’s unique approach to integration, which utilizes intuitive AI, music therapy, and group support.
Nue Life is a public benefits corporation, and its entire founding team is made up of people of colour and women. Learn how Juan Pablo Cappello used spiritual wisdom to create a conscious business in his talk, 4 Pillars of Conscious Startups.
This will be an inspiring event for anyone who dreams of running a tech startup or wants to bring conscious leadership to their workplace.
Over 90% of people experienced increased sexual desire and satisfaction after taking MDMA. But that’s not the only way it can improve your sex life.
Mindcure (MCUR) is studying MDMA-assisted-therapy as a treatment for Hypoactive Sexual Desire Disorder (HSDD), which is characterized by low sex drive and emotional distress.
The goal is to use MDMA to get to the root cause of the issue, which may be a history of negative sexual experiences and relationships or struggles with self worth or body image.
Algernon Pharmaceuticals (AGN) found that microdoses of DMT can increase the growth of neurons in the brain by up to 40%. An upcoming study will see if this can benefit stroke patients.
Phase I of the study, which is awaiting approval in the UK, will determine the maximum amount of DMT that can be taken without producing a psychedelic effect. Phase II will test repeated doses on acute and recovering stroke patients.
Last year, Awakn Life Sciences (AWKN) found that MDMA-assisted therapy helped alcoholics reduce alcohol consumption by 85% – from an average of 130.6 units per week to just 18.7.
Now, the company is exploring a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to treat alcohol use disorder across Europe, where alcohol is one of the top five causes of disease and disability in most countries. Awakn may license MAPS’ pre-clinical data to get the treatment to market faster.
In a preclinical animal model, Wesana Health (WESA) found that a single high dose of psilocybin rapidly improved depressive behaviours for 14 days. A regimen of psilocybin microdoses and CBD was able to sustain the results and reduced depressive behaviours by an additional 64%.
Let’s keep the microdosing evidence coming!
How can DMT be improved to better treat addiction? How do our genetics influence our psychedelic experiences? How does ketamine change our brain wave patterns? Does music make psychedelic therapy more effective?
These are all questions that Entheon Biomedical (ENBI) is answering with ongoing clinical research. Learn what they’ve discovered so far and their next steps at our Mental Health Town Hall this February 3rd!
We’ll be joined by Entheon’s Founder and CEO, Scientific Advisor, and Communications Manager to discuss the company’s findings and the future of psychedelic therapy. Register now for free to get the inside scoop 👇
Did you know that potent psychedelics like 5-MeO-DMT and bufotenin come from the venom of the Colorado River Toad?
With growing demand to study these compounds and increased recreational use, wild populations of the toad are threatened in some areas.
Alvarius Research Inc. recently developed a toad conservation program to address this issue. The company is also collaborating with Egret Bioscience to develop synthetic “toad-free” versions of the compounds.
An ancient South American empire called the Wari Empire may have used a hallucinogenic beer to maintain its power.
The Wari people brewed a beer-like drink with seeds from the vilca tree, which contain a psychedelic compound called bufotenin (one of the substances found in toad venom!).
Archeologists believe that Wari leaders served the drink at feasts to strengthen social connections with guests from surrounding regions. Guests likely had a euphoric or spiritual experience, compelling them to “acknowledge the power of their hosts or feel the need to owe them a favor in the future,” explains one archeology expert.
Could this be why the empire maintained political control for hundreds of years? 🤔
If you’re looking to try microdosing, what better way to get started than with a community of like-minded individuals.
Dose Day is a microdosing peer support network that connects you with a small group with similar intentions and interests. Meet with your group weekly to see how the power of community can support you on your journey.
Whether you’re an artist, an executive, a consciousness junkie or someone looking to improve their mental health, there is a group for you.
Plus, half the fee supports palliative care patients with end-of-life anxiety.
Psygen Industries Ltd. is building Canada’s first manufacturing facility dedicated to synthetic psychedelics. The company received authorization to produce and sell psilocybin, psilocin, LSD, DMT, mescaline, and 2C-B through a Health Canada Dealer’s License. It has already established over 20 supply agreements with domestic and international companies 👏
Numinus Wellness (NUMI) is enrolling patients for a multi-site study on MDMA for PTSD, which will be sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). The study received approval from both Health Canada and the Institutional Ethics Review Board.
Eleusis, a UK-based company focused on psilocybin therapy for depression, is planning to go public through a $446M merger with Silver Spike Acquisition Corp. II (SPKB). Eleusis will apply to have its shares listed on the NASDAQ under the symbol ‘ELEU’.
Red Light Holland (TRIP) is collaborating with an advocacy group called the Psychedelic Medicine Alliance Washington to promote a bill that would legalize guided psilocybin sessions in Washington State. The company has hired a lobbyist with experience in cannabis regulation and is launching a social media campaign and educational events to raise awareness about the benefits of psilocybin.
Red Light Holland (TRIP) is collaborating with an advocacy group called the Psychedelic Medicine Alliance Washington to promote a bill that would legalize guided psilocybin sessions in Washington State. The company has hired a lobbyist with experience in cannabis regulation and is launching a social media campaign and educational events to raise awareness about the benefits of psilocybin.
Toronto, Ontario–(Newsfile Corp. – January 11, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles is excited to have Registered Shareholders as of November 26th 2021 at the Company’s Annual General and Special Meeting (“AGSM“) later this morning at 11am. Please refer to the notice received for access to the meeting.
Red Light Holland is pleased to announce that Brad J Lamb, Chairman of the Board of Directors will Chair today’s AGSM and that Bruce Linton, Red Light Holland Chairman of the Advisory Board will provide a live Advisory Board activity update.
Red Light Holland is also looking forward to a live Q&A session, immediately after the AGSM, with CEO Todd Shapiro, CTIO Sarah Hashkes and CFO David Ascott.
Once again, Red Light Holland’s AGSM is later today, January 11th, 2022 at 11am – available online via the link provided in the notice of meeting.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to, statements with respect to the Q&A session.
Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: Red Light Holland’s expectation that Brad J Lamb, Bruce Linton, Todd Shapiro, Sarah Hashkes and David Ascott will join the AGSM; unforeseen events such as the COVID-19 pandemic, emergency health situations, or potential internet outages and connectivity issues. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of Brad J Lamb, Bruce Linton, Todd Shapiro, Sarah Hashkes or David Ascott to attend the AGSM due to emergency health situations, COVID-19 and/or Internet outages or connectivity issues.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Toronto, Ontario–(Newsfile Corp. – January 6, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles, is pleased to announce that it has received the second report, produced by Shaman Pharma Corp. and CCrest Laboratories Inc. under a Health Canada Controlled Drugs & Substances license. This report was focused on perfecting potency assays and identifying variables such as water content and size that might influence the amount and the characteristics determining active ingredients (psilocybin and psilocin) in the truffles as a step towards creating a standardized consistent dose from naturally occurring psychoactive truffles.
“We continue to move towards creating a standardized consistent dose from naturally occurring psilocybin truffles that can potentially benefit both the hopeful recreational and medicinal markets,” said Todd Shapiro, CEO and Director of Red Light Holland. “We are learning through market research and anecdotal movements that many people prefer naturally occurring psilocybin over synthetics – so it’s exciting that Red Light Holland with the help of Shaman Pharma are once again working aggressively within all legal means, and adding to the scientific knowledge of these natural products. We hope the Canadian Government will see the need to provide patients, who are approved to use natural psilocybin, with an ability to access our tested products of known dosage.”
“The progress we have made in the year 2021 was simply groundbreaking which positioned our companies to start this new year with incredible momentum. We look forward to continuing and expanding our collaboration with Red Light Holland.” said Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories. “The timely news regarding the Special Access Program is in line with our expectations and we are fully committed to exceeding the exemplary regulatory standards put forward by Health Canada, hoping it will inspire the health authorities of other countries to follow without hesitation.”
Now that a precise and specific analysis method (SP1-173-L) has been determined next steps will be taken to test its robustness and accuracy. Other substances were also identified in the truffles and more bibliography will be needed to identify other alkaloid compounds that might be present in the truffles such as Norbaeocystin, Baeocystin and Aeruginascin which will help research the possibility of an “entourage effect” in naturally occurring truffles.
From the report, it can be inferred that the size is not affecting the concentrations of psilocybin and psilocin, but the water content is an essential factor. In the case of large-sized truffles (Galindoi and Tampanensis) removal of water content, without degrading psilocybin, is a challenging task which in turn affects the extract concentrations. It can be observed from these results that the laboratory was successfully able to bring the raw material to their anhydrous state while maintaining the same ratio of active ingredients.
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/2017/109252_a4a3dcc8d47728da_001full.jpg.
Future analysis will also expand research using scientific methods applied in pharmaceutical drug development, for instance determining the exact influence of light on the degradation of psilocybin and psilocin by doing a forced degradation study, and performing stability studies under various conditions. These studies can illustrate the chemical stability of the molecule which further facilitates the development of stable experimental design and suitable storage conditions. This information will aid in the development of lab-scale production projects to provide practitioners with quality-controlled psilocybin for their patients.
On January 5, 2022, the Controlled Substances Directorate of Health Canada announced that amendments were published and came into force immediately to restore the possibility for practitioners who are allowed to prescribe drugs to request access to restricted drugs, including psilocybin, through Health Canada’s Special Access Program (SAP). With the regulations now amended, practitioners who are allowed to prescribe drugs can, on behalf of patients with serious or life-threatening conditions, request access to restricted drugs through the SAP when other therapies have failed, are unsuitable, or are not available in Canada, among other conditions.
While all SAP requests will continue to be assessed on a case-by-case basis, and there is no guarantee that access to restricted drugs will be granted through the SAP, this much anticipated step forward validates the importance of the work performed at CCrest Laboratories with psilocybin truffles from Red Light Holland. Canada is leading the way in providing practitioners with a path for patients to access psilocybin, and it is critical to make it readily available through a legal and quality-controlled supply chain, and that practitioners can rely on specific, precise and consistent dosage.
Red Light Holland continues to establish itself as a leader in the recreational sector and push for legal, responsible and safe access to natural psychedelic truffles/mushrooms while Scarlette Lillie Science and Innovation pursues research and development, technology, and applied science.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
About Shaman Pharma Corp.
Shaman Pharma is a federally registered Canadian corporation with the mission to power outstanding psychedelic life science innovation. Accelerating time-to-market through its portfolio of assets, Shaman launches and consolidates revenue-driven pharma-biotech life sciences ventures focused on supplying psychedelic drugs & novel active ingredients.
Forward-Looking Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Red Light Holland. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to: statements with respect to the Company creating a standardized consistent dose from naturally occurring psychoactive truffles; statements with respect to Health Canada’s Special Access Program, including the Company’s expectations with respect to exceeding any potential regulatory standards set by such program; statements with respect to further evaluation and testing of the Company’s naturally occurring psilocybe truffles by CCrest Laboratories for scientific and medical purposes; the potential of the Company’s products being used for scientific and medical purposes; the Company’s ability to establish itself as the leader in the recreational psychedelics sector.
Forward-looking information is based on a number of key expectations and assumptions made by Red Light Holland, including without limitation: the COVID-19 pandemic impact on the Canadian economy and Red Light Holland’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Red Light Holland’s business; there will be a demand for Red Light Holland’s products in the future; no unanticipated expenses or costs arise; the Company will be able to continue to develop products that are allowed to be imported and sold under Health Canada’s import permit; and the partnership with Shaman Pharma Corp. will help Red Light Holland to achieve its business goals. Although the forward-looking information contained in this news release is based upon what the Company believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to continue as a going concern; the inability of the Company to obtain all necessary governmental and/or other regulatory approvals, licenses, and permits necessary to operate and expand the Company’s facilities; the effect of regulatory and/or political change and its effect on the legislation and regulations surrounding the psychedelics industry including SAP; negative perception of the medical-use and adult-use psilocybin industry; the inability of CCrest to complete the planned testing of the Company’s products; the inability of the Company to create a standardized dose; the potential unviability of psilocybin for medical and/or scientific purposes; the inability of the Company to continue its growth; the Company’s limited operating history; reliance on management; the Company’s requirements for additional financing; and competition for mental health and wellness investments.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Here’s what’s in store for you in today’s issue:
🍄 The cure for the worst pain known to humans
🍄 Combining antidepressants and psilocybin
🍄 More positive findings from biggest psilocybin trial
🍄 Psychedelic cream?
🍄 And more.
In this episode of the Daily Mushroom Podcast, we have the CEO of Silo Wellness, Douglas Gordon. Silo Wellness offers legal, psychedelic retreats in Jamaica and Oregon. Their mission is heavily rooted in the education around the physical and mental benefits of mushrooms. We hope you enjoy this one!
Do patients need to come off of antidepressants before trying psilocybin therapy?
New research from MindMed (MNMD) and Liechti Labs suggests that it’s not necessary – and there are actually benefits of combining the two.
Escitalopram (aka Lexapro) did not affect the way psilocybin was processed and helped reduce negative side effects like anxiety and high blood pressure.
COMPASS Pathways (CMPS) announced additional findings from the world’s largest psilocybin trial for depression.
In addition to reduced depression scores, patients showed improvements in anxiety, daily functioning, cognition, and quality of life. Just one day after the treatment, patients had increased positive feelings such as “interested, excited, strong” and decreased negative feelings like “distressed, upset, afraid.”
Psycheceutical Inc., a private Florida company, is developing a unique way to deliver psychedelics – through a cream or patch applied to the back of the neck. This method allows psychedelics to enter the brain in just 5-10 minutes without entering the bloodstream, which reduces negative side effects.
Quantified Citizen is a platform made in collaboration with Paul Stamets to accelerate health research. It allows anyone to participate in studies anonymously from their phone.
The platform was used to conduct the world’s largest mobile microdosing study, which revealed that microdosers exhibit lower levels of depression, anxiety, and stress.
It’s not too late to participate – download the app here to join the study!
For years, Brad Badelt suffered from debilitating cluster headaches (which are often called “suicide headaches” and described as the worst pain known to humans.
After seeing countless neurologists, chiropractors, acupuncturists, and naturopaths, he would still experience the horrible headaches several times a day for weeks on end.
After taking one dose of shrooms, things finally changed.
“When I woke the next morning, I felt different: the mental fog brought on by my cluster headaches was gone. For the next twelve months, I remained headache free. Every year since, I’ve downed a dose of shrooms, and every year my cluster headaches have remained in remission.”
The Wakeful Integration Journal is your guide to transformation.
It’s the ultimate tool to help you prepare for, navigate, and deeply integrate your psychedelic experiences. The journal features:
If you want to start with microdosing rather than a full-on trip, the Wakeful Intention Journal is for you! It guides you through a 6-week microdosing protocol and helps you set intentions, notice patterns, and integrate your insights.
Support the Kickstarter here to receive a journal and begin your transformation journey!
MYND Life Sciences (MYND) received $45,600 in government funding to support a psilocybin research project on treatment resistant depression and neuroinflammation. The project will run now until March 2022.
Novamind (NM) partnered with Bienstar Wellness to develop the first network of integrative mental health clinics in Latin America. The companies plan to bring psychedelic medicine to Uruguay, Brazil, Mexico, Peru, and Panama.
PharmaTher (PHRM) was granted a Japanese patent for KETBET, a combination of ketamine and betaine anhydrous that can be used for various mental health and pain disorders. Betaine anhydrous enhances the antidepressant effect of ketamine while reducing the side effects.
Telescope Innovations (TELI) acquired the rights to the University of British Columbia’s research on synthetic psilocybin in exchange for 1M common shares at $0.99 each.
Bright Minds Biosciences (DRUG) announced that its drug discovery program has synthesized hundreds of patentable psychedelic compounds. Researchers are optimizing the most encouraging molecules and aim to announce the lead molecule early next year.
Shanti Therapeutics, a subsidiary of Global Wellness (GWS), is awaiting ethics committee approval to conduct one of the first studies on MDMA for pain management.
These companies announced their financial highlights:
The new limits will allow more researchers to study the drugs! Read more…
A Florida Rep. filed a bill to decriminalize all illegal substances and implement rehabilitative health intervention or civil fines instead. Read more…
A startup in the Netherlands is making biodegradable “living coffins” out of mushroom mycelium!
Not only do the coffins enrich the soil, but they allow “people to become one with nature again.”
After months of testing, the first funeral using a mushroom coffin was a success.
Silo Wellness (SILO) launched a line of functional mushroom products in collaboration with Bob Marley’s family!
The Marley One line features:
Use promo code DAILYMUSHROOM20 to get 20% off!
Nov 29 – Numinus (NUMI) Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans Read more…
Nov 29 – atai Life Sciences (ATAI) Increases its Ownership Position in COMPASS Pathways (CMPS) Read more…
Nov 30 – Cybin (CYBN) Announces FDA IND and IRB Approvals for Clinical Trial to Treat Frontline Clinicians with COVID-Related Distress Read more…
Dec 2 – Ketamine One (MEDI) Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD Read more…
Dec 2 – Tryp Therapeutics (TRYP) Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia Read more…
Nov 26 – Delic Corp’s (DELC) Ketamine Wellness Centers Opening Salt Lake City & Reno Locations Read more…
Company announces 56% increase in the number of stores selling its iMicrodose products in the Netherlands
Six-month revenues of $1,080,875
Toronto, Ontario–(Newsfile Corp. – November 29, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, today reported its financial results for the three and six months ended September 30, 2021. Unless otherwise stated, all amounts are expressed in Canadian dollars. The Company is also pleased to announce a significant increase in the number of Smart Shop retail stores selling its iMicrodose products in the Netherlands.
Commenting on Red Light Holland’s second quarter performance, Todd Shapiro, Chief Executive Officer stated, “I am pleased with the progress that we have made during the second quarter. We were focused on iMicrodose and Maka product development with the goal of increasing future revenues and related margins. The quarter saw us close two important strategic acquisitions and continue to realize revenues and gross profit from our existing operations. Our acquisition of a majority interest in Acadian Exotic Mushrooms (AEM) is expected to commence significant revenue generation in March 2022. Increasing our revenue is a core focus and we continue to identify and analyze merger and acquisition transactions while remaining cautious with our spending habits.”
With regards to the increased store presence in the Netherlands, Hans Derix, Red Light Holland President, added “We have increased the number of stores that sell our iMicrodose psychedelic products from 25 to 39 (a 56% increase) in the Netherlands. This is a significant increase in market presence that was completed under the backdrop of retail pressure attributed to the continuing global pandemic. We have also developed and launched a newly branded Maka line of products. As a result of these efforts, we expect increased revenue related to psychedelic products and functional mushroom products in the coming quarters.”
Sarah Hashkes, Red Light Holland’s CTIO added, “Rec and Tech is Red Light Holland’s core focus. We have seen a strong increase in privacy first data collection with our iMicrodose end consumers in the Netherlands via our iMicro App. Our Tele-counseling support remains a phenomenal option and we are also thrilled to have entered into a ‘mold making stage agreement’ with Hotopfun factory in China to continue to build out Wisdom smart home devices, inspired by the mycelium network, in preparation for mass manufacturing Q1 of 2022. Red Light Holland continues to execute its strategic initiatives and we are proud of our unique and innovative technology and their alternative revenue streams.”
SUMMARY OF THE QUARTER ENDED SEPTEMBER 30, 2021
Both the Financial Statements and Management’s Discussion and Analysis for the three and six months ended September 30, 2021 are now available on SEDAR.
About Red Light Holland
The Company is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-8747 (TRIP)
Email: todd@redlighttruffles.com
Website: https://redlighttruffles.com/
Forward-Looking Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such information include statements with respect to: Acadian Exotic Mushrooms Ltd and its ability to commence revenue generating deliveries by March 2022; the Company’s ability to close merger and acquisition transactions in both the psychedelic and exotic farm industries; the increase in Smart Shop retail store presence translating into increased sales of the Company’s psychedelic products; the Company’s plans to begin mass manufacturing of the Wisdom smart home devices in Q1 of 2022; and expectations for other economic, business, and/or competitive factors.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, expectations regarding future growth and expansion of the operations of the business; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; changes in demand for the Company’s product offerings; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the psychedelics industry, including the global regulatory landscape and enforcement related to psychedelics; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the psychedelics industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com, including the Company’s annual information form for the year ended March 31, 2020.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws
The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
